Glucose-Dependent Insulinotropic Polypeptide (GIP) is an incretin hormone secreted by the K-cells of the small intestine in response to the ingestion of nutrients. Its primary physiological role is to stimulate the pancreas to release insulin, but it only does so when blood glucose levels are elevated. In addition to its insulinotropic effects, GIP is involved in lipid metabolism and has receptors in the central nervous system that play a role in energy balance and appetite regulation.
In modern metabolic pharmacology, GIP has emerged as a key therapeutic target. When used in combination with GLP-1 receptor agonists, GIP appears to enhance the weight-loss effects and potentially improve the tolerability of the treatment. It helps to regulate how the body stores and utilizes fat, making it a critical component of the complex hormonal signaling network that governs overall metabolic health and body weight.
The definitive guide by Russell Clark, FNP-C, APRN